Cargando…
A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy
BACKGROUND: Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PG...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466217/ https://www.ncbi.nlm.nih.gov/pubmed/23056167 http://dx.doi.org/10.1371/journal.pone.0040388 |
_version_ | 1782245650331598848 |
---|---|
author | Chao, Xu Zhang, Zhuoli Guo, Lili Zhu, Jingjing Peng, Mingli Vermorken, Alphonsus J. M. Van de Ven, Wim J. M. Chen, Chao Cui, Yali |
author_facet | Chao, Xu Zhang, Zhuoli Guo, Lili Zhu, Jingjing Peng, Mingli Vermorken, Alphonsus J. M. Van de Ven, Wim J. M. Chen, Chao Cui, Yali |
author_sort | Chao, Xu |
collection | PubMed |
description | BACKGROUND: Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PGMNPs) as a drug carrier of the chemotherapy compound doxorubicin (DOX) in vitro; 2) to evaluate the therapeutic efficiency of DOX-conjugated PGMNPs (DOX-PGMNPs) using an EMF-guided delivery in vivo. METHODS: First, DOX-PGMNPs were synthesized and the cytotoxicity of DOX-PGMNPs was assessed in vitro. Second, upon intravenous administration of DOX-PMGPNs to H22 hepatoma cell tumor-bearing mice, the DOX biodistribution in different organs (tissues) was measured. The antitumor activity was evaluated using different treatment strategies such as DOX-PMGPNs or DOX-PMGPNs with an EMF-guided delivery (DOX-PGMNPs-M). RESULTS: The relative tumor volumes in DOX-PGMNPs-M, DOX-PGMNPs, and DOX groups were 5.46±1.48, 9.22±1.51, and 14.8±1.64, respectively (each p<0.05), following treatment for 33 days. The life span of tumor-bearing mice treated with DOX-PGMNPs-M, DOX-PGMNPs, and DOX were 74.8±9.95, 66.1±13.5, and 31.3±3.31 days, respectively (each p<0.05). CONCLUSION: This simple and adaptive nanoparticle design may accommodate chemotherapy for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers in the near future. |
format | Online Article Text |
id | pubmed-3466217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34662172012-10-10 A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy Chao, Xu Zhang, Zhuoli Guo, Lili Zhu, Jingjing Peng, Mingli Vermorken, Alphonsus J. M. Van de Ven, Wim J. M. Chen, Chao Cui, Yali PLoS One Research Article BACKGROUND: Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PGMNPs) as a drug carrier of the chemotherapy compound doxorubicin (DOX) in vitro; 2) to evaluate the therapeutic efficiency of DOX-conjugated PGMNPs (DOX-PGMNPs) using an EMF-guided delivery in vivo. METHODS: First, DOX-PGMNPs were synthesized and the cytotoxicity of DOX-PGMNPs was assessed in vitro. Second, upon intravenous administration of DOX-PMGPNs to H22 hepatoma cell tumor-bearing mice, the DOX biodistribution in different organs (tissues) was measured. The antitumor activity was evaluated using different treatment strategies such as DOX-PMGPNs or DOX-PMGPNs with an EMF-guided delivery (DOX-PGMNPs-M). RESULTS: The relative tumor volumes in DOX-PGMNPs-M, DOX-PGMNPs, and DOX groups were 5.46±1.48, 9.22±1.51, and 14.8±1.64, respectively (each p<0.05), following treatment for 33 days. The life span of tumor-bearing mice treated with DOX-PGMNPs-M, DOX-PGMNPs, and DOX were 74.8±9.95, 66.1±13.5, and 31.3±3.31 days, respectively (each p<0.05). CONCLUSION: This simple and adaptive nanoparticle design may accommodate chemotherapy for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers in the near future. Public Library of Science 2012-10-08 /pmc/articles/PMC3466217/ /pubmed/23056167 http://dx.doi.org/10.1371/journal.pone.0040388 Text en © 2012 Chao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Chao, Xu Zhang, Zhuoli Guo, Lili Zhu, Jingjing Peng, Mingli Vermorken, Alphonsus J. M. Van de Ven, Wim J. M. Chen, Chao Cui, Yali A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy |
title | A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy |
title_full | A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy |
title_fullStr | A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy |
title_full_unstemmed | A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy |
title_short | A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy |
title_sort | novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466217/ https://www.ncbi.nlm.nih.gov/pubmed/23056167 http://dx.doi.org/10.1371/journal.pone.0040388 |
work_keys_str_mv | AT chaoxu anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT zhangzhuoli anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT guolili anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT zhujingjing anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT pengmingli anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT vermorkenalphonsusjm anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT vandevenwimjm anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT chenchao anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT cuiyali anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT chaoxu novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT zhangzhuoli novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT guolili novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT zhujingjing novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT pengmingli novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT vermorkenalphonsusjm novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT vandevenwimjm novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT chenchao novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy AT cuiyali novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy |